Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy

Avelumab is indicated for the management of Merkel cell carcinoma, a rare and aggressive neuroendocrine skin cancer. Its regulatory approval followed the positive outcome of a Phase 2 trial on 88 patients with stage IV disease, which excluded patients with immunodeficiency due to HIV, a risk factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Homsi, Mohammed U., Mostafa, Mai, Fahim, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103370/
https://www.ncbi.nlm.nih.gov/pubmed/30140209
http://dx.doi.org/10.1159/000490636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103370/
https://www.ncbi.nlm.nih.gov/pubmed/30140209
http://dx.doi.org/10.1159/000490636

Ejemplares similares